Boehringer Ingelheim has announced that Senvelgo (velagliflozin oral solution), a revolutionary new treatment for cats with diabetes, is now available in Great Britain.
Senvelgo is a convenient, once-daily, oral solution that cat owners can give with a small amount of food or directly into the cat’s mouth.
Senvelgo ushers in a new era of care that enables diabetic cats and their owners to live normal lives despite this chronic condition.
Senvelgo greatly simplifies treatment for cat owners and removes the need for twice daily insulin injections.
It controls blood sugar levels usually within a week without the risk of symptomatic hypoglycaemia and provides the benefit of simple dosing according to bodyweight.
As it is just once-daily it is more likely to fit in with owner’s busy lifestyles.
While feline diabetes is one of the most common endocrine disorders in cats, studies have unfortunately shown that up to 20 percent of diagnosed cats are euthanased within a year due to the complexities of existing treatments.
Ten percent of cats are euthanased following diagnosis because of owners not wanting to inject with insulin, and a further 10 percent of cats are euthanased within one year because of lack of success or compliance with insulin.
The key benefits of Senvelgo for vets and cat owners include:
- Once-daily, flavoured, oral solution that can be administered directly into the mouth or with a small amount of food
- Simple dosing according to bodyweight
- No risk of symptomatic hypoglycaemia
- Glycaemic control can be achieved within a week
- No need for glucose curves to determine dosage
- Easy storage – no refrigeration necessary
- Less plastic waste – 1 reusable oral syringe vs 180 insulin syringes – based on one bottle of Senvelgo lasting three months for a five-kilogram cat and assuming a new syringe for cats on a twice daily insulin injection regime
“This is the development in diabetes management we have been waiting many years for; a practical oral therapy to treat this challenging disease,” said Samantha Taylor, BVetMed(Hons), CertSAM, DipECVIM-CA, MANZCVS, FRCVS.
Nikki Milne, business head of pet, at Boehringer Ingelheim added: “Senvelgo oral solution is a convenient feline therapeutic product and demonstrates our dedication to continuously deliver and drive new innovative, science-backed and easy-to-use feline therapeutic products to address the unique needs of cats.
“We are really excited to bring Senvelgo oral solution to the market because it will really support cat owners and their diabetic cats to continue to enjoy a normal life, despite this chronic disease.”
Senvelgo oral solution is now available in Great Britain.
To support vet professionals with using Senvelgo, there is available a new Senvelgo toolkit that includes a veterinary management guide, CPD webinar, cat owner leaflet and homecare journal, along with websites for vets and cat owners.
Vets can find out more by contacting their Boehringer Ingelheim Territory Manager or by visiting the vet professional website.
Vets can also find out more about Senvelgo by visiting stand F40 at the London Vet Show.
